Eli Lilly and Company (LLY) — closed signal from October 23, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on January 21, 2026.
Predicted vs. what happened
What happened
Reached its target in 13 days.
The thesis — published October 23, 2025
Eli Lilly blends stability with growth, led by obesity and Alzheimer's treatments. Recent U.S. news points to a larger Alzheimer's market, and cash-flow math suggests the stock may be priced too low. Sales have grown about 18% a year over five years. Shares look washed out but the bigger trend still leans upward. Over the next 0-3 months, a steady climb is plausible as demand is clear and investors favor durable growers.
Primary drivers
- Growing U.S. Alzheimer's market expands the potential customer base
- Strong and rising demand for its obesity medicines keeps sales building
- Stock looks washed out while the recent trend still tilts upward
- Solid business results with investor views that are not overly hot
How it played out
LLY: target reached in 13 days
Lyra published LLY at $818.42 on 2025-10-23 for a short-term window ending 2026-01-21. The thesis expected 15% growth. It pointed to obesity and Alzheimer's treatments, a growing U.S. Alzheimer's market, strong obesity-medicine demand, a washed-out stock with an upward trend, and solid business results with investor views that were not overly hot.
Inside the window, LLY reached the $939.80 target in 13 days. It later peaked at $1133.95 on 2026-01-08, with a 38.6% peak gain. It ended the window at $1078.52. The thesis played out clearly.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.